首页> 外文期刊>BMC Nephrology >Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases
【24h】

Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases

机译:澳大利亚腹膜透析患者的链球菌性腹膜炎:287例的预测因素,治疗和结局

获取原文
           

摘要

Background There has not been a comprehensive, multi-centre study of streptococcal peritonitis in patients on peritoneal dialysis (PD) to date. Methods The predictors, treatment and clinical outcomes of streptococcal peritonitis were examined by binary logistic regression and multilevel, multivariate poisson regression in all Australian PD patients involving 66 centres between 2003 and 2006. Results Two hundred and eighty-seven episodes of streptococcal peritonitis (4.6% of all peritonitis episodes) occurred in 256 individuals. Its occurrence was independently predicted by Aboriginal or Torres Strait Islander racial origin. Compared with other organisms, streptococcal peritonitis was associated with significantly lower risks of relapse (3% vs 15%), catheter removal (10% vs 23%) and permanent haemodialysis transfer (9% vs 18%), as well as a shorter duration of hospitalisation (5 vs 6 days). Overall, 249 (87%) patients were successfully treated with antibiotics without experiencing relapse, catheter removal or death. The majority of streptococcal peritonitis episodes were treated with either intraperitoneal vancomycin (most common) or first-generation cephalosporins for a median period of 13 days (interquartile range 8–18 days). Initial empiric antibiotic choice did not influence outcomes. Conclusion Streptococcal peritonitis is a not infrequent complication of PD, which is more common in indigenous patients. When treated with either first-generation cephalosporins or vancomycin for a period of 2 weeks, streptococcal peritonitis is associated with lower risks of relapse, catheter removal and permanent haemodialysis transfer than other forms of PD-associated peritonitis.
机译:背景技术迄今为止,尚无针对腹膜透析(PD)患者的链球菌性腹膜炎的全面,多中心研究。方法对2003年至2006年间66个中心的澳大利亚PD患者进行二元logistic回归分析和多级,多元泊松回归分析,以评估链球菌性腹膜炎的预测,治疗和临床结局。结果187例链球菌性腹膜炎(4.6%)所有腹膜炎发作中的256例)。它的发生是由原住民或托雷斯海峡岛民的种族起源独立预测的。与其他生物相比,链球菌性腹膜炎的复发风险显着降低(3%vs 15%),拔除导管(10%vs 23%)和永久性血液透析转移(9%vs 18%)以及持续时间较短住院时间(5天比6天)。总体而言,有249名患者(87%)成功用抗生素治疗,未出现复发,拔除导管或死亡的情况。多数链球菌性腹膜炎发作均用腹膜内万古霉素(最常见)或第一代头孢菌素治疗,中位时间为13天(四分位间距为8-18天)。最初的经验性抗生素选择不会影响预后。结论链球菌性腹膜炎不是PD的常见并发症,在土著患者中更为常见。当用第一代头孢菌素或万古霉素治疗2周时,与其他形式的PD相关性腹膜炎相比,链球菌性腹膜炎的复发,导管移除和永久性血液透析转移的风险较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号